R&D | December 31, 2025
Sinopia Biosciences scores NIH grant to supercharge AI-driven drug discovery
The funding will accelerate Sinopia’s data-driven drug discovery efforts
The funding will accelerate Sinopia’s data-driven drug discovery efforts
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Applications include detailed scientific rationale and supporting clinical evidence
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The study met its primary endpoint with flying colors
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
